Search hospitals > New York > New York
Icahn School of Medicine at Mount Sinai
Claim this profileNew York, New York 10029
Global Leader in Cancer
Global Leader in Parotid Gland Cancer
Conducts research for Lymphoma
Conducts research for Multiple Myeloma
Conducts research for Solid Tumors
1544 reported clinical trials
157 medical researchers
Summary
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Parotid Gland Cancer, Lymphoma, Multiple Myeloma, Solid Tumors and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,390 conditions. There are 157 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Deborah Doroshow, MD, PhD, and Thomas Marron, MD PhD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Parotid Gland Cancer
Global LeaderStage IV
Stage III
EGFR positive
Top PIs
Edward J. KimUniversity of California Davis Comprehensive Cancer Center1 year of reported clinical research
Studies Parotid Gland Cancer
Studies Cervical Adenocarcinoma
33 reported clinical trials
70 drugs studied
Matthew Galsky, M.D.Icahn School of Medicine at Mount Sinai5 years of reported clinical research
Studies Bladder Cancer
Studies Cancer
16 reported clinical trials
29 drugs studied
Deborah Doroshow, MD, PhDMount Sinai Hospital4 years of reported clinical research
Studies Cancer
Studies Solid Tumors
17 reported clinical trials
41 drugs studied
Thomas Marron, MD PhDIcahn School of Medicine at Mount Sinai1 year of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Cancer
14 reported clinical trials
24 drugs studied
Clinical Trials running at Icahn School of Medicine at Mount Sinai
Breast Cancer
Crohn's Disease
Bladder Cancer
Ovarian Cancer
Multiple Myeloma
Cancer
Myelofibrosis
Multiple Sclerosis
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Combination Immunotherapy + Radiation
for Cancer
This is a combination of 4 therapies, three of which are used to treat a single "target site" of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into the blood stream (intravenous or "IV"). 1. Radiation: The target site --lymph node or tumor (the one what will be injected) --will get two small treatments of radiation. Radiation is often times used to shrink and kill tumors in patients with certain types of lymphoma, breast cancer and head and neck cancer, however, the dose of radiation that you will receive --one dose on day one of the clinical trial and one dose on day two --is 10 to 20 time less radiation that you would receive for treatment of these cancers. 2. Flt3L/CDX-301 is an immune cell growth factor, similar to white blood cell growth factors (Neupogen or Neulasta) or red blood cell growth factors (EPO or Epogen) that you may have received to help protect your blood cells previously. Flt3L causes your body to make more immune cells, specifically a type of immune cell called "dendritic cells". 3. Poly-ICLC is an immune cell activating factor. Its function is to turn on the immune cells that have been brought to the tumor by Flt3L. 4. Pembrolizumab is an antibody (a type of human protein) that is being tested to see if it will allow the body's immune system to kill your tumor cells. Pembrolizumab is approved for use by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with many different types of cancer including head and neck cancer. Pembrolizumab is not FDA approved to treat patients with non-Hodgkin's lymphoma or metastatic breast cancer, as it has not been effective at treating these cancers when used alone. While most people do not have immediate side effects when this medication is given, it has the ability to cause side effects for.
Recruiting2 awards Phase 1 & 22 criteria
Combo Therapy
for Breast Cancer
This trial tests a new drug, OP-1250, combined with either ribociclib or alpelisib in cancer patients. It aims to see if these combinations are safe and can better stop cancer growth.
Recruiting1 award Phase 1
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Icahn School of Medicine at Mount Sinai?
Where is Icahn School of Medicine at Mount Sinai located?
Who should I call to ask about financial aid or insurance network?
What insurance does Icahn School of Medicine at Mount Sinai accept?
What awards or recognition has Icahn School of Medicine at Mount Sinai received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.